预约演示
更新于：2025-02-07
Fosfomycin Tromethamine
磷霉素氨丁三醇
更新于：2025-02-07
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 (1988-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C7H18NO7P |
InChIKeyQZJIMDIBFFHQDW-LMLSDSMGSA-N |
CAS号78964-85-9 |
关联
27
项与 磷霉素氨丁三醇 相关的临床试验CTIS2024-513465-39-00
Clinical Efficacy of oral Fosfomycin Trometamol and Cefixime in the Treatment of Acute Bacterial Prostatitis (CEFOSPROST): a comparative, randomized, open, multicenter trial. - CEFOSPROST
CTR20242961
江苏联环药业股份有限公司研制的磷霉素氨丁三醇颗粒（3 g）与Zambon Switzerland Ltd.生产的磷霉素氨丁三醇颗粒（3 g）在中国健康受试者中进行的随机、开放、单剂量、两序列、两周期、交叉、空腹状态下的生物等效性研究
NCT06017479
Effectiveness of Single Dose Fosfomycin and Single Dose Levofloxacin as Pre-urodynamic Antibiotic Prophylaxis for Urinary Tract Infection Prevention in Post-Urodynamic Examination
100 项与 磷霉素氨丁三醇 相关的临床结果
登录后查看更多信息
100 项与 磷霉素氨丁三醇 相关的转化医学
登录后查看更多信息
100 项与 磷霉素氨丁三醇 相关的专利（医药）
登录后查看更多信息
361
项与 磷霉素氨丁三醇 相关的文献（医药）2025-01-01ENVIRONMENTAL RESEARCH
A phenotypic study of the resistome in a peri-urban ecosystem
Article
作者: González Domenech, Carmen María ; López Guarnido, Olga ; González Román, Ana Carmen ; García Valdés, Luz María ; Espigares Rodríguez, Elena ; Dib, Amira Leila ; Román, Ana Carmen González
Since the discovery of antibiotics, the dispersion of resistance genes has increased exponentially, leading to the current state in which it has become increasingly difficult to achieve an effective treatment for infectious diseases. The enormous capacity for genetic exchange between microorganisms is causing resistance genes to be able to reach all environments, even those where there is no anthropogenic impact or exposure to these drugs. In this work, a phenotypic study of the resistome has been conducted in a peri-urban ecosystem (Granada, Spain), wherein the resistance to 32 antibiotics of 710 bacterial strains isolated from 70 samples from different ecological niches with varying levels of exposure to antibiotics and anthropic action has been determined. The study of resistances using phenotypic procedures constitutes a very useful and complementary alternative to genomic methods. The obtained results show a high percentage of resistance in all the subsystems analysed, stating high multi-resistance profiles. Vancomycin and erythromycin were the antibiotics to which the highest levels of resistance were observed, whereas the lowest levels were obtained in chloramphenicol. Regarding the environments studied, the highest percentages of resistance were found in wastewater, farms and food. It should be noted that in natural soil samples (not exposed to antibiotics or anthropogenic activities), worrying levels of resistance to practically all the groups of antibiotics analysed were detected. These results support the generally accepted conclusion that an appropriate control and management of wastewater and solid waste that may contain antibiotics or resistant bacteria is really important to prevent the wide propagation of the resistome in the environment.
2024-09-02Urologiia (Moscow, Russia : 1999)
New Prospects for Conservative Treatment of Chronic Recurrent Cystitis in Women: Experience with the Drug Superlymph®
Article
作者: Khanaliev B, V ; Gankovskaya L, V ; Gankovskaya, Gankovskaya L.V. ; Khasanova, Khasanova E.M. ; Sudilovskaya, Sudilovskaya V.V. ; Tevlina E, V ; Sudilovskaya V, V ; Tevlin, Tevlin K.P. ; Nasaeva E, D ; Nasaeva, Nasaeva E.D. ; Tevlin K, P ; Khasanova E, M ; Khanaliev, Khanaliev B.V. ; Tevlina, Tevlina E.V.
INTRODUCTION:
Chronic recurrent cystitis is a common and difficult problem of modern urology. Traditional use of antimicrobial drugs often cannot lead to the long-term remission.
AIM:
To evaluate the efficacy and safety of using different dosages and routes of the drug Superlymph in rectal and vaginal suppositories 10 U and 25 U in patients with chronic recurrent cystitis.
MATERIALS AND METHODS:
A randomized comparative clinical study in parallel groups included 60 patients aged from 18 to 80 years with a diagnosis of chronic recurrent bacterial uncomplicated cystitis. All study participants were randomized into three groups. In Group 1 (n=25), Superlymph suppositories 25 U were prescribed rectally once a day for 20 days. In group 2 (n=25), Superlymph suppositories 10 U were administered vaginally 2 times a day, for 20 days. In accordance with the prescription information, Superlymph 10 U/25 U can be used vaginally or rectally depending on the gender. In addition, it is possible to change the route of administration, for example, Superlymph 25 U one suppository once a day or Superlymph 10 U, one suppository 2 times a day in the morning and in the evening. The duration of the course is from 10 to 20 days. The main aim of the study was to compare an influence of various route of administration of Superlymph in women with frequent relapses of cystitis on the urothelium according to biopsy results, as well as on the symptoms of recurrent cystitis. The reparative effect of Superlymph was evaluated as well. In the control group (n=10), standard therapy was administered (fosfomycin trometamol 3.0 g once, and then, on the next day from the start of therapy, nitrofurantoin 100 mg three times a day for 5 days). The study consisted of screening, therapy and follow-up stages. The duration of therapy was 20 days. All groups did not differ significantly in the main baseline characteristics.
RESULTS:
The drug Superlymph demonstrated efficacy as monotherapy of uncomplicated lower urinary tract infection in women compared with standard treatment. Rectal administration of the drug was more effective than vaginal. This was primarily manifested by a decrease in the level of urothelial metaplasia by the end of the study by 41% in the group of rectal suppositories and by 9% for the vaginal suppositories. In the control group, no changes in the level of metaplasia were found. A symptom scale showed an improvement of 36% in the group of rectal suppositories, 25% in the group of vaginal suppositories, and 19% in the control group. Improvements in the quality-of-life score were 50.8%, 33.9%, and 31.1%, respectively. The mean pelvic pain symptom scale score improved by 30%, 23%, and 13%, while a decrease in the mean leukocytes level in urine was most significant in the group of vaginal suppositories, by 39%. The respective indicators in the group of rectal suppositories and the control group were 27% and 21%, respectively. Innate immune factors were also assessed. The evaluation of gene expression levels in the bladder mucosa after using Superlymph was also performed. A significant decrease in TLR4 gene expression by 3 times, TNF gene expression by 4.2 times, and HBD1 expression by 2.7 times was found, which indicates a significant decrease in the level of inflammation in the bladder mucosa.
CONCLUSION:
The immunomodulator Superlymph, representing a complex of natural antimicrobial peptides and cytokines, has demonstrated efficacy as monotherapy of chronic recurrent cystitis in women compared to standard treatment. Rectal route of administration was more effective than vaginal. This was primarily manifested by a decrease in the level of urothelial metaplasia by the end of the study. Therefore, the rectal suppositories should be used in older patients with a long history of the cystitis as intermittent therapy.
2024-09-02Urologiia (Moscow, Russia : 1999)
Current approaches to diagnosis and treatment of urinary tract infections during pregnancy
Review
作者: Neimark, Neimark A.I. ; Shperling N, V ; Neimark A, I ; Shperling, Shperling M.I. ; Kovaleva Yu, S ; Shperling M, I ; Kovaleva, Kovaleva Yu.S. ; Shperling, Shperling N.V.
Urinary tract infections (UTIs) are one of the leading causes of extragenital pathology in pregnant women, occurring in to 5-7% of women. Despite the asymptomatic course in many cases, even uncomplicated UTIs carry the risk of complications for both the woman and the fetus due to the high risk of ascending infection. Therefore, timely diagnosis and rational therapy are key to preventing adverse outcomes. The diagnosis is based on characteristic clinical and laboratory signs. The basis for the treatment of UTIs is timely antibacterial therapy (ABT). At the same time, approaches to the empirical selection of a specific drug are identical between different types of infections, due to their etiological similarity. Rational ABT varies depending on the severity of the UTIs. In case of complicated course requiring hospitalization, preference is given to parenteral forms, while in those with uncomplicated UTIs, oral drugs are chosen in order to achieve high compliance. Oral ABT for uncomplicated UTI in pregnant women include nitrofurans, fosfomycin trometamol, and third-generation cephalosporins. Among the latter, cefixime seems to be most rational due to high sensitivity of the main uropathogens (E. coli), high efficiency, safety and compliance with treatment in pregnant women.
100 项与 磷霉素氨丁三醇 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 泌尿道感染 | - | 1988-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 126 | (Pre-urodynamic Fosfomycin) | 獵網積鏇築膚製淵顧鬱(鑰願艱獵簾憲願製獵齋): Odds Ratio (OR) = 0.8 (95% CI, 0.4 ~ 1.95), P-Value = 0.660 | - | 2024-10-09 | ||
(Pre-urodynamic Levofloxacin) | |||||||
临床2期 | - | - | 齋鹹衊網簾衊繭構鹽願(觸襯鹽繭壓憲範顧願廠) = 糧鬱夢獵網築夢壓鑰獵 繭簾衊願齋築網鏇廠齋 (鑰繭遞鹹襯簾壓鏇壓鑰 ) 更多 | 积极 | 2023-04-01 | ||
Preoperative Amikacin 1 gr I.V. | 齋鹹衊網簾衊繭構鹽願(觸襯鹽繭壓憲範顧願廠) = 鏇膚鑰網構齋鬱獵網築 繭簾衊願齋築網鏇廠齋 (鑰繭遞鹹襯簾壓鏇壓鑰 ) 更多 | ||||||
临床4期 | 62 | (Strategy 1) | 夢顧觸鬱選餘憲夢餘夢(簾廠壓鹽齋範壓構醖繭) = 製積艱簾選廠襯獵鑰膚 廠淵艱願積鹹膚獵憲鏇 (製鑰憲選憲製製簾齋鏇, 獵繭製構積鹹鑰鑰顧廠 ~ 窪蓋鑰鏇齋鬱餘鑰網壓) 更多 | - | 2020-12-19 | ||
(Strategy 2) | 夢顧觸鬱選餘憲夢餘夢(簾廠壓鹽齋範壓構醖繭) = 鏇鹹襯積顧膚願遞鏇憲 廠淵艱願積鹹膚獵憲鏇 (製鑰憲選憲製製簾齋鏇, 積醖壓衊積艱鬱鹽憲範 ~ 範鹹繭鬱鏇鑰廠窪夢艱) 更多 | ||||||
临床4期 | - | Fosfomycin trometamol + trimethoprim-sulfamethoxazole (Group 1) | 積蓋遞觸積鹹鹽製繭鹽(齋鹽餘願淵夢醖蓋蓋壓) = 網壓齋淵顧願製膚衊範 艱構鬱觸構蓋夢網鏇願 (淵繭膚積憲繭蓋鏇遞構 ) | - | 2018-10-01 | ||
Trimethoprim-sulfamethoxazole (Group 2) | 積蓋遞觸積鹹鹽製繭鹽(齋鹽餘願淵夢醖蓋蓋壓) = 遞窪積蓋衊選簾鏇膚顧 艱構鬱觸構蓋夢網鏇願 (淵繭膚積憲繭蓋鏇遞構 ) | ||||||
临床2期 | 18 | 糧襯夢構築觸獵齋壓窪(夢糧鏇觸遞醖範願鏇廠) = 襯鏇顧遞衊蓋膚製壓鹹 積願餘鏇壓餘鹹鑰窪鹽 (廠鬱淵齋願鹽選壓繭襯, 獵淵餘選衊衊選鏇獵遞 ~ 網遞壓憲蓋淵窪齋遞網) 更多 | - | 2017-10-19 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用